myocardin related transcription factor AGenealiases: BSAC · MAL · MKL · MKL1 · MRTF-A
Q-omics provides the consensus-scored MRTFA profile across patient tissues and cancer cell-line models. MRTFA expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, MRTFA is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, MRTFA RNA expression shows 18,781 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, HNSC, and ACC as cancer lineages where MRTFA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRTFA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRTFA survival associations across molecular data types. MRTFA RNA expression shows survival associations in the most cancer types (17), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRTFA RNA expression–survival associations across cancer types. High MRTFA expression shows unfavorable associations in ACC, OV and LIHC, but favorable associations in SCLC, ESCA and BRCA. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for MRTFA RNA expression.
This table summarizes MRTFA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRTFA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRTFA shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, LIHC, STAD and CHOL. The HNSC box plot shows higher MRTFA RNA expression in tumor versus normal tissue (log2 FC = +0.995, t-test p < 0.001).
This table shows molecular features associated with MRTFA in patient tissues and cancer cell lines. In patient samples, MRTFA shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRTFA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
